On Sunday German health group Siemens Healthineers said it was buying U.S cancer treatment device maker Varian Medical Systems Inc for $16.4 billion, giving it a foothold in the oncology sector.
The takeover seeks to create a global leader in cancer care solutions by 2025. Industrial conglomerate Siemens, which spun off Healthineers in 2018 but retains control, said it will provide bridge financing for the deal.
Under the agreed transaction, Siemens Healthineers will acquire all shares in Varian for $177.50 each in cash, representing a 24% premium to the U.S. company’s closing price on Friday and 42% above its 30-day weighted average.
“With this takeover, we are significantly strengthening our position – in addition to cardiology and neurology – in the field of oncology,” Chief Financial Officer Jochen Schmitz told Reuters in an interview.
Through the deal, Siemens Healthineers is addressing a long-term rise in the incidence of cancer – from 14 million cases worldwide in 2010 to a forecast 25 million in 2030. That translates into an addressable market of $20 billion that is forecast to grow at an annual rate of between 6% and 10%, the company said in a presentation on the deal.
The transaction, first reported by Bloomberg, is subject to approval by Varian shareholders and regulators. It is expected to close in the first half of 2021 and be accretive to Siemens Healthineers’ adjusted basic earnings per share within 12 months of that.
“With Siemens Healthineers, we will transform care for a greater number of patients worldwide, as well as broaden opportunities for our employees as part of a larger and more global organization,” Varian President and Chief Executive Officer Dow Wilson said.
Conglomerate Siemens is effectively putting its balance sheet to work to fund the deal, providing a bridging loan of 15.2 billion euros ($17.9 billion) to Healthineers.
The medical technology unit aims to replace 50% of that through a rights issue this year, subject to market conditions. Siemens said in its statement that it expressly welcomed the deal and would raise the money for the bridging loan by issuing bonds. As a result, its stake in Healthineers would be diluted to about 72% from 85%.
Healthineers also pre-released fiscal third quarter results instead of on Monday due to the acquisition announcement. They showed its revenue declined 6.9% year-on-year on a comparable basis to 3.3 billion euros due to the impact of the coronavirus pandemic.